首页> 外文期刊>Archivum immunologiae et therapiae experimentalis >Profile of Inflammation-Associated Proteins in Early Post-Transplant Samples of Patients After Allogeneic Hematopoietic Stem Cell Transplantation: a Preliminary Study
【24h】

Profile of Inflammation-Associated Proteins in Early Post-Transplant Samples of Patients After Allogeneic Hematopoietic Stem Cell Transplantation: a Preliminary Study

机译:在同种异体造血干细胞移植后早期移植后患者早期移植后样品中的炎症相关蛋白质的概况:初步研究

获取原文
获取原文并翻译 | 示例

摘要

Allogeneic hematopoietic stem cell transplantation (aHSCT) is used as a curative treatment in severe hematological and immunological disorders. Despite clear improvement of the aHSCT outcome, substantial proportion of patients still suffers from severe complications, including graft-versus-host disease (GvHD). The aim of this study was, therefore, to identify inflammation-associated molecules deregulated in the early serum samples of the patients after aHSCT and nominate markers associated with particular aHSCT parameters/complications. Serum concentrations of 92 inflammation-associated proteins were measured in samples obtained from 80 aHSCT patients 14 days after transplantation and from 23 healthy control subjects by a novel sensitive proximity extension assay technology using Proseek Multiplex Inflammation I kit. Serum profiles of inflammatory proteins in patients after aHSCT were substantially different from those observed in control subjects and related to underlying disease status before transplantation. Particularly, the difference between aHSCT patients and controls reached significance level for 57 analytes (40 upregulated, 17 downregulated in aHSCT patients). The concentration of several markers was associated with the level of donor/recipient HLA match (TGF-alpha: P-corr = 0.025, HGF: p(corr) = 0.036) and with complete donor chimerism at day +30 after allografting (DNER: p(corr) = 0.042). None of the markers was significantly associated with acute and chronic GvHD after correction. More than half of investigated proteins significantly differed between the samples from aHSCT patients and healthy control subjects as a consequence of the "cytokine storm'' after aHSCT. Comparisons of patient's subgroups based on specific biological/clinical parameters revealed much less evident differences; nevertheless, we nominated several markers associated with the level of donor/recipient HLA match and post-transplant chimerism.
机译:同种异体造血干细胞移植(AHSCT)用作严重血液学和免疫障碍中的治疗方法。尽管有明确提高AHSCT结果,但大部分患者仍然存在严重的并发症,包括移植物与宿主疾病(GVHD)。因此,本研究的目的是鉴定AHSCT和提名标记与特定AHSCT参数/并发症相关的提名标记物中鉴定患者早期血清样品中的炎症相关分子。在从80AHSCT患者在移植后14天的样品中测量92个炎症相关蛋白的血清浓度,并通过使用PROSEEK多重炎症I套件通过新型敏感的接近延伸测定技术从23例健康对照受试者获得。 AHSCT后患者炎症蛋白的血清谱与对照对象观察到的血清谱不同,并且在移植前与潜在的疾病状态相关。特别是,AHSCT患者和对照之间的差异达到57分析物的显着性水平(40次上调,17例在AHSCT患者中下调)。几个标记的浓度与供体/受体HLA匹配的水平有关(TGF-α:P-Corr = 0.025,HGF:P(Corr)= 0.036),并在同一天的+30日内与完全供体斜切相(DNER: p(corr)= 0.042)。在校正后没有任何标记与急性和慢性GVHD显着相关。来自AHSCT患者的样品和健康对照受试者的样品在AHSCT之后的“细胞因子风暴”的后果中,超过一半的调查蛋白质在患者的“细胞因子风暴”的结果中显着不同。基于特定的生物/临床参数的患者亚组的比较显得不那么明显的差异;尽管如此,我们提名与供体/受体HLA匹配水平和移植后斜切相相关的几个标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号